Apellis Pharmaceuticals (APLS) Competitors $19.55 +0.34 (+1.78%) As of 01:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLS vs. VTRS, QGEN, ROIV, LNTH, RVMD, BBIO, LEGN, TGTX, TLX, and BPMCShould you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Apellis Pharmaceuticals vs. Viatris Qiagen Roivant Sciences Lantheus Revolution Medicines BridgeBio Pharma Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Apellis Pharmaceuticals (NASDAQ:APLS) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Is APLS or VTRS more profitable? Viatris has a net margin of -5.87% compared to Apellis Pharmaceuticals' net margin of -34.97%. Viatris' return on equity of 16.46% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Apellis Pharmaceuticals-34.97% -103.11% -28.96% Viatris -5.87%16.46%7.09% Does the MarketBeat Community favor APLS or VTRS? Apellis Pharmaceuticals received 325 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 66.79% of users gave Apellis Pharmaceuticals an outperform vote while only 34.85% of users gave Viatris an outperform vote. CompanyUnderperformOutperformApellis PharmaceuticalsOutperform Votes34866.79% Underperform Votes17333.21% ViatrisOutperform Votes2334.85% Underperform Votes4365.15% Do institutionals and insiders hold more shares of APLS or VTRS? 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 6.8% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Viatris shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, APLS or VTRS? Apellis Pharmaceuticals has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Do analysts rate APLS or VTRS? Apellis Pharmaceuticals presently has a consensus price target of $45.28, indicating a potential upside of 134.79%. Viatris has a consensus price target of $10.50, indicating a potential upside of 21.75%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Apellis Pharmaceuticals is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apellis Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.65Viatris 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Which has stronger valuation and earnings, APLS or VTRS? Viatris has higher revenue and earnings than Apellis Pharmaceuticals. Viatris is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApellis Pharmaceuticals$781.37M3.10-$528.63M-$1.59-12.13Viatris$14.74B0.70$54.70M-$0.53-16.27 Does the media prefer APLS or VTRS? In the previous week, Viatris had 17 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 40 mentions for Viatris and 23 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.77 beat Viatris' score of 0.02 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apellis Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 6 Positive mention(s) 30 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral SummaryApellis Pharmaceuticals beats Viatris on 11 of the 19 factors compared between the two stocks. Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLS vs. The Competition Export to ExcelMetricApellis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.42B$6.75B$5.51B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-9.497.3222.5518.49Price / Sales3.10239.19394.97102.66Price / CashN/A65.8538.1834.62Price / Book11.766.436.694.25Net Income-$528.63M$143.21M$3.22B$248.31M7 Day Performance9.94%1.24%1.11%1.12%1 Month Performance-14.97%6.09%3.59%3.68%1 Year Performance-58.12%-3.34%15.65%5.19% Apellis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLSApellis Pharmaceuticals4.1182 of 5 stars$19.55+1.8%$45.28+131.6%-56.5%$2.47B$781.37M-9.67770Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageVTRSViatris1.835 of 5 stars$7.57+0.1%$10.50+38.7%-27.2%$9.04B$14.74B-10.2337,000Upcoming EarningsQGENQiagen3.6936 of 5 stars$40.51-0.5%$47.83+18.1%+4.0%$9.01B$1.98B112.806,030Upcoming EarningsAnalyst RevisionROIVRoivant Sciences2.2052 of 5 stars$10.04-1.1%$17.50+74.3%+6.6%$7.16B$122.59M-66.93860Positive NewsLNTHLantheus3.9766 of 5 stars$100.62-0.7%$129.43+28.6%+56.8%$6.89B$1.53B16.74700Upcoming EarningsPositive NewsRVMDRevolution Medicines3.762 of 5 stars$36.56-0.5%$66.67+82.3%+8.3%$6.80B$742,000.00-10.18250Upcoming EarningsAnalyst ForecastPositive NewsBBIOBridgeBio Pharma4.5547 of 5 stars$33.51-1.1%$53.00+58.2%+49.7%$6.37B$221.90M-11.76400Earnings ReportAnalyst ForecastOptions VolumeNews CoverageLEGNLegend Biotech2.6407 of 5 stars$32.24-1.7%$79.00+145.0%-20.1%$5.92B$627.24M-33.941,070TGTXTG Therapeutics3.3232 of 5 stars$36.97-3.5%$40.67+10.0%+233.2%$5.81B$329.00M-369.66290Upcoming EarningsNews CoveragePositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-3.0%$22.00+35.7%N/A$5.48B$783.21M0.00N/AAnalyst RevisionNews CoverageBPMCBlueprint Medicines2.5644 of 5 stars$84.18-0.6%$124.95+48.4%-2.0%$5.38B$508.82M-77.94640Analyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies VTRS Alternatives QGEN Alternatives ROIV Alternatives LNTH Alternatives RVMD Alternatives BBIO Alternatives LEGN Alternatives TGTX Alternatives TLX Alternatives BPMC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
